ArticleBMC endocrine disorders2026
Association of the triglyceride-glucose index with inflammatory markers and dysregulation of adipokines in patients with metabolic syndrome.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association of Genetic Variants inInternational journal of molecular sciences · 2026Article
- Circulating Adiponectin and Omentin Across Cardiometabolic Phenotypes: Links to Atherogenic Indices in Prediabetes and New-Onset Type 2 Diabetes.International journal of molecular sciences · 2026Article
- Development and validation of age- and gender-specific reference intervals for the triglyceride-glucose index in a large Chinese healthy adult population.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundTriglyceride-glucose (TyG) index has emerged as a reliable surrogate marker for insulin resistance and an early indicator of metabolic dysfunction. However, its association with inflammatory markers and adipokine dysregulation in patients with metabolic syndrome (MetS) remains poorly understood. This study aimed to investigate the association of the TyG index with inflammatory biomarkers and adipokine profiles in adults diagnosed with MetS.
methodsThis cross-sectional study included 190 adults (aged 20-50 years) with metabolic syndrome (MetS), recruited from primary healthcare centers in Iran. We collected anthropometric and biochemical data, and calculated the TyG index, classifying participants into quartiles based on their TyG values. Fasting serum glucose (FSG), insulin, and lipid profiles were measured. Insulin resistance was assessed using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR). In addition, inflammatory markers including tumor necrosis factor alpha (TNF-α), Interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hs-CRP) long with serum levels of adipokines including leptin, adiponectin, resistin, visfatin, vaspin, and omentin-1 were measured using standardized assays.
resultsHigher TyG quartiles were associated with increased levels of insulin, HOMA-IR, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), TNF-α, leptin, and resistin, and decreased levels of adiponectin (all p < 0.05). There were no significant differences in high-density lipoprotein cholesterol (HDL-c), IL-6, hs-CRP, visfatin, vaspin, or omentin-1. These associations remained significant even after adjusting for age, sex, body mass index (BMI), smoking status, and physical activity.
conclusionOur findings suggest that the TyG index reflects not only insulin resistance and atherogenic dyslipidemia, but also low-grade inflammation and adipokine imbalance in patients with MetS. Due to its simplicity and cost-effectiveness, the TyG index could be a useful tool for early metabolic risk assessment and identifying adipose tissue dysfunction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.